Rifaximin for IBS without constipation

February 2011
Internal Medicine Alert;2/15/2011 Supplement 2, p23
The article reports that the use of rifaximin for patients with irritable bowel syndrome (IBS) without constipation has provided a statistically significant improvement in global symptoms, bloating, abdominal pain and stool consistency.


Related Articles

  • Rifaximin for IBS without constipation. Elliott, William T. // Infectious Disease Alert;Mar2011 Clinical Bri, p1 

    The article reports on a study published in the "New England Journal of Medicine," which found that rifaximin, an oral antibiotic, can treat symptoms of irritable bowel syndrome (IBS).

  • Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS. Osborne, Randy // BioWorld Today;4/5/2010, Vol. 21 Issue 64, p1 

    The article reports on the approval of Salix Pharmaceuticals' antibiotic Xifaxan for irritable bowel syndrome (IBS). The studies TARGET 1 and TARGET 2 have met primary and secondary endpoints in IBS. There are three forms of IBS, namely, diarrhea-predominant, constipation-predominant and mixed,...

  • Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Pimentel, Mark; Morales, Walter; Chua, Kathleen; Barlow, Gillian; Weitsman, Stacy; Kim, Gene; Amichai, Meridythe; Pokkunuri, Venkata; Rook, Emily; Mathur, Ruchi; Marsh, Zachary; Amichai, Meridythe M // Digestive Diseases & Sciences;Jul2011, Vol. 56 Issue 7, p2067 

    Unlabelled: Recent evidence suggests a role for gut bacteria and antibiotics in the pathophysiology and treatment of irritable bowel syndrome (IBS), respectively. While the benefits of the antibiotic rifaximin have demonstrated efficacy and durable improvement in symptoms over...

  • Antibiotic Treatment Effective in Treating Irritable Bowel Syndrome.  // Journal of Medical Sciences;2011, Vol. 11 Issue 2, p125 

    No abstract available.

  • Salix Anticipates Receipt of FDA Complete Response Letter on XIFAXAN(R) 550 Mg Tablets Supplemental New Drug Application.  // Biomedical Market Newsletter;3/21/2011, p481 

    The article reports on Salix Pharmaceuticals Ltd.'s anticipation of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the XIFAXAN(R) (rifaximin) 550 milligrams supplemental New Drug Application (sNDA). It says that Salix expects receiving CRL for the proposed...

  • Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. Talley, Nicholas; Holtmann, Gerald; Walker, Marjorie // Journal of Gastroenterology;Jun2015, Vol. 50 Issue 6, p601 

    Functional gastrointestinal disorders (FGIDs) are common and distressing. They are so named because a defined pathophysiology in terms of structural or biochemical pathways is lacking. Traditionally FGIDs have been conceptualized as brain-gut disorders, with subgroups of patients demonstrating...

  • Microbiome, antibiotics and irritable bowel syndrome. Ahmad, O. F.; Akbar, A. // British Medical Bulletin;Dec2016, Vol. 120 Issue 1, p91 

    Introduction: Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal (GI) disorder. Increasing evidence implicates the GI microbiota in IBS pathogenesis and its modulation represents an emerging therapeutic strategy. Sources of data: Original and review articles were...

  • Rifaximin for IBS without constipation. Elliott, William T. // Primary Care Reports;Mar2011 Pharmacology Watch, p1 

    The article presents a research study on the use of rifaximin for the relief of symptoms of irritable bowel syndrome (IBS) published in a 2011 issue of the "New England Journal of Medicine."

  • Alosetron to return to market. Young, Donna // American Journal of Health-System Pharmacy;7/15/2002, Vol. 59 Issue 14, p1323 

    Reports on the U.S. Food & Drug Administration's approval of a supplemental drug that permits restricted marketing of alosetron hydrochloride by GlaxoSmithKline PLC. Reasons of the company for previously withdrawing the drug; Drug dosage and administration; Effectiveness in treating irritable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics